Skip to main content
LIFECOME BIOCHEMISTRY CO., LTD. logo

LIFECOME BIOCHEMISTRY CO., LTD. — Investor Relations & Filings

Ticker · 002868 ISIN · CNE100002QH2 LEI · 65560089EP03NANEN790 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,742 across all filing types
Latest filing 2025-04-28 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002868

About LIFECOME BIOCHEMISTRY CO., LTD.

https://www.pclifecome.com

Lifecome Biochemistry Co., Ltd. focuses on the research, development, and large-scale production of fermentation-based veterinary pharmaceuticals and feed additives. The company’s core product portfolio includes Bacitracin Zinc, Bacitracin Methylene Disalicylate (BMD), and Colistin Sulfate, available in both active pharmaceutical ingredient (API) and premix forms. These biochemical products are primarily utilized in the livestock and poultry sectors to manage enteric health and improve feed efficiency. The organization operates advanced fermentation and purification facilities, maintaining compliance with international Good Manufacturing Practices (GMP) and various global regulatory standards. By leveraging specialized biotechnological processes, the company provides high-purity solutions aimed at enhancing animal nutrition and disease prevention across international markets.

Recent filings

Filing Released Lang Actions
北京博星证券投资顾问有限公司关于绿康生化股份有限公司详式权益变动报告书之财务顾问核查意见
Capital/Financing Update Classification · 95% confidence The document is titled as a "详式权益变动报告书" (Detailed Equity Change Report) and contains a "财务顾问核查意见" (Financial Advisor's Verification Opinion) related to a significant equity change involving a listed company, 绿康生化股份有限公司. It details the equity transfer agreement, shareholding changes, legal and regulatory compliance, financial advisor's due diligence, and post-transaction plans. The document references relevant laws and regulations such as the Securities Law, the Acquisition Management Measures, and disclosure format standards (Format Guidelines No. 15 and 16) which are specific to equity change and acquisition disclosures. The content is comprehensive, includes financial data, legal compliance, and management plans related to a change in control of a listed company. This matches the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising, financing activities, or capital structure changes, including significant equity transfers and control changes. It is not an announcement of a report but the detailed report itself, and it is not a merger proxy or tender offer filing (which would be MA or TAR). Therefore, the appropriate classification is CAP with high confidence.
2025-04-28 Chinese
简式权益变动报告书（义睿投资）
Major Shareholding Notification Classification · 100% confidence The document is a detailed report about a change in shareholding by an information disclosure obligor (杭州义睿投资合伙企业) in the listed company 绿康生化股份有限公司. It includes legal references to Chinese securities laws, detailed descriptions of share transfer agreements, shareholding percentages before and after the transaction, approval procedures, and declarations of compliance. The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report" or "Equity Change Report". This type of document corresponds to notifications about changes in major shareholdings or significant share ownership levels crossing thresholds. It is not an annual report, earnings release, or management report. It is not a proxy statement or voting results announcement. It is a formal disclosure of a major shareholding change due to share transfer agreements. Therefore, the appropriate classification is Major Shareholding Notification (Code: MRQ). The document length (15,000 characters) and detailed content confirm it is the report itself, not just an announcement of a report publication or a regulatory filing.
2025-04-28 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding changes in accounting policies by the company 绿康生化股份有限公司. It references new accounting standards and interpretations issued by the Ministry of Finance and states that these changes do not require board or shareholder approval and will not materially affect financial results. The document is relatively short (1172 characters) and serves as a formal notification of accounting policy changes rather than a full financial report or audit. It does not contain financial statements or detailed financial analysis. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-04-28 Chinese
公司2025年度财务预算报告
Regulatory Filings Classification · 85% confidence The document is titled '2025年度财务预算报告' which translates to '2025 Annual Financial Budget Report'. It contains projected financial figures and assumptions for the upcoming fiscal year rather than actual financial results or audited data. The content focuses on budget planning and forecast rather than reporting past performance or regulatory compliance. It is not an annual report, interim report, earnings release, or audit report. It is also not an announcement or a certification. Given the nature of the document as a financial budget plan, it does not fit neatly into the provided categories for official financial reports or announcements. The closest fitting category is Regulatory Filings (RNS) as a fallback for miscellaneous filings that do not fit other categories.
2025-04-28 Chinese
独立董事2024年度述职报告 （范学斌）
Board/Management Information Classification · 95% confidence The document is a detailed annual performance report of an independent director (范学斌) for the year 2024, describing his duties, attendance, communication with shareholders, internal control, and other governance-related activities. It is not a financial report, earnings release, or audit report. It focuses on the director's role, responsibilities, and governance matters. The document length is 2863 characters, which is relatively short but contains substantive content about the director's work rather than just an announcement. This fits the category of Board/Management Information (MANG), which covers announcements or reports about changes or activities of board members or senior management. Therefore, the appropriate classification is MANG with high confidence.
2025-04-28 Chinese
会计师事务所对非标意见涉及事项专项说明
Audit Report / Information Classification · 95% confidence The document is titled as a special explanation related to the audit report for the fiscal year 2024 of 绿康生化股份有限公司. It discusses the audit opinion issued, specifically a clean (unqualified) opinion with an explanatory paragraph regarding significant uncertainties related to the company's ability to continue as a going concern. The document references Chinese auditing standards and regulatory requirements for disclosure of non-standard audit opinions. It includes details about the audit scope, materiality, and limitations on use. The document is a standalone audit report or explanation related to the audit, not the full annual report or financial statements. It is not a brief announcement or certification but a detailed audit explanation. Therefore, it fits the category of Audit Report / Information (AR). The document length is 1344 characters, which is consistent with a detailed audit report explanation rather than a short announcement or certification letter. FY 2024
2025-04-28 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.